Effects of exogenous progesterone on gestation length, foetal survival and colostrum yield in ewes

Intestinal gene expression profiles of piglets benefit from maternal supplementation with a yeast mannan-rich fraction during gestation and lactation

The objective was to study the effect of maternal supplementation with a yeast cell wall-based product containing a mannan-rich fraction (MRF) during gestation and lactation on piglet intestinal gene expression. First parity sows were fed experimental gestation and lactation diets with or without MRF (900 mg/kg). After farrowing, piglets were fostered within treatment, as necessary. Sow and litter production performance data were collected until weaning. On day 10 post farrowing, jejunum samples from piglets were collected for gene expression analysis using the Affymetrix Porcine GeneChip array. Most performance parameters did not differ between the treatments. However, protein (P<0.01), total solids less fat (P<0.03) and the concentration of immunoglobulin G (IgG) in milk were greater (P<0.05) in the MRF-supplemented group. Gene expression results using hierarchical clustering revealed an overall dietary effect. Further analysis elucidated activation of pathways involved in tissue development, functioning and immunity, as well as greater cell proliferation and less migration of cells in the jejunum tissue. In conclusion, feeding the sow MRF during pregnancy and lactation was an effective nutritional strategy to bolster colostrum and milk IgG that are essential for development of piglet immune system and gut. In addition, the gene expression patterns affected by the passive immunity transfer showed indicators that could benefit animal performance long term.

Altrenogest treatment during late pregnancy did not reduce colostrum yield in primiparous sows

The decrease in circulating concentrations of progesterone is the lactogenic trigger in many species. The aim of the present study was to determine the effect of an orally active progestogen, altrenogest, administered in late gestation, on lactogenesis in sows. Gilts were treated with altrenogest (20 mg/d) from d 109 to 112 of gestation (ALT112, n = 6) or d 113 (ALT113, n = 8) or were not treated (control, n = 9). Colostrum production, estimated from the BW gains of the piglets, was measured during 24 h starting at the onset of parturition. Colostrum samples were collected at the onset of parturition until 48 h later. Jugular blood samples were taken from d -8 prepartum until d 3 postpartum. Altrenogest treatment extended the gestation length of ALT113 sows in comparison with control sows (116.3 vs. 114.7 d; P < 0.05). Litter size and litter weight at birth did not differ between groups (P > 0.1). Estimated colostrum yield was not reduced in altrenogest-treated sows compared with control sows (4.20 kg) and tended to be greater in ALT112 (4.73 kg) than in ALT113 sows (3.74 kg; P = 0.09). Altrenogest reduced endogenous progesterone concentrations during the 2 d prepartum in ALT113 relative to control sows (P < 0.05), likely because luteolysis occurred earlier in relation to parturition in ALT113 sows. Altrenogest reduced estradiol-17beta concentrations during the 2 d prepartum in ALT113 (P < 0.05) and ALT112 (P < 0.1) sows. Altrenogest treatment did not influence the timing of the prepartum peak of prolactin in relation to parturition. The ALT113 sows had lesser (P < 0.05) concentrations of lactose in plasma and a lesser Na:K ratio in colostrum after parturition than Control and ALT112 sows, indicating that the junctions between their mammary epithelial cells were tighter. Concentrations of colostral IgG in sows that received altrenogest tended to be less than in control sows (P = 0.08). In conclusion, altrenogest administered from d 109 to 112 or 113 of pregnancy did not affect lactogenesis in sows, possibly because the treatment delayed farrowing and main hormonal changes without affecting the relative chronology of these changes.

“Natural” progesterone: information on fetal effects

BACKGROUND

A variety of progestational agents have been used therapeutically and evaluated for adverse effects over the last 50 years. However, progesterone itself has come into use as a therapeutic agent only recently with the development of an orally bioavailable "micronized" preparation.

METHODS

The current review examines progesterone adverse effects as identified in the larger literature on the toxicity of progestational agents and pharmacokinetics.

RESULTS

Progesterone has cytoplasmic and membrane receptors in a variety of reproductive and nonreproductive tissues including the brain and is a potent inhibitor of GnRH. Limited information is available on progesterone receptors and actions in the fetus. Concern about exogenous progestagen effects on fetal reproductive tract development have led to considerable human research over the years, but this literature review demonstrates that contemporary developmental toxicology research on progesterone is lacking.

CONCLUSIONS

Progesterone is a potent, multi-faceted endocrine agent with an expanding therapeutic profile and a minimal scientific database for evaluating safe use during pregnancy.